CorMedix Inc. (CRMD)
CorMedix Statistics
Share Statistics
CorMedix has 65.18M shares outstanding. The number of shares has increased by 10.7% in one year.
Shares Outstanding | 65.18M |
Shares Change (YoY) | 10.7% |
Shares Change (QoQ) | 8.62% |
Owned by Institutions (%) | 39.06% |
Shares Floating | 63.65M |
Failed to Deliver (FTD) Shares | 46.35K |
FTD / Avg. Volume | 3.32% |
Short Selling Information
The latest short interest is 7.08M, so 11.67% of the outstanding shares have been sold short.
Short Interest | 7.08M |
Short % of Shares Out | 11.67% |
Short % of Float | 11.95% |
Short Ratio (days to cover) | 5.63 |
Valuation Ratios
The PE ratio is -26.6 and the forward PE ratio is 21.18. CorMedix's PEG ratio is 0.
PE Ratio | -26.6 |
Forward PE | 21.18 |
PS Ratio | 10.97 |
Forward PS | 1.4 |
PB Ratio | 0.01 |
P/FCF Ratio | -0.01 |
PEG Ratio | 0 |
Enterprise Valuation
CorMedix Inc. has an Enterprise Value (EV) of 148.34M.
EV / Earnings | -8.27 |
EV / Sales | 3.41 |
EV / EBITDA | -0.01 |
EV / EBIT | -6.64 |
EV / FCF | 0 |
Financial Position
The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.
Current Ratio | 3.39 |
Quick Ratio | 3.16 |
Debt / Equity | 0 |
Total Debt / Capitalization | 0 |
Cash Flow / Debt | -97898.22 |
Interest Coverage | -614.1 |
Financial Efficiency
Return on equity (ROE) is 0% and return on capital (ROIC) is -0.02%.
Return on Equity (ROE) | 0% |
Return on Assets (ROA) | 0% |
Return on Capital (ROIC) | -0.02% |
Revenue Per Employee | $679,252.66 |
Profits Per Employee | $-280,156.56 |
Employee Count | 64 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | -1.39B |
Effective Tax Rate | 0.07 |
Stock Price Statistics
The stock price has increased by 58.96% in the last 52 weeks. The beta is 1.53, so CorMedix's price volatility has been higher than the market average.
Beta | 1.53 |
52-Week Price Change | 58.96% |
50-Day Moving Average | 10.48 |
200-Day Moving Average | 8.29 |
Relative Strength Index (RSI) | 25.26 |
Average Volume (20 Days) | 1.4M |
Income Statement
In the last 12 months, CorMedix had revenue of 43.47M and earned -17.93M in profits. Earnings per share was -304.56.
Revenue | 43.47M |
Gross Profit | 40.28M |
Operating Income | -22.36M |
Net Income | -17.93M |
EBITDA | -22.36B |
EBIT | -22.36M |
Earnings Per Share (EPS) | -304.56 |
Balance Sheet
The company has 40.65M in cash and 517.01K in debt, giving a net cash position of 40.13M.
Cash & Cash Equivalents | 40.65M |
Total Debt | 517.01K |
Net Cash | 40.13M |
Retained Earnings | -339.63B |
Total Assets | 118.85M |
Working Capital | 17.95M |
Cash Flow
In the last 12 months, operating cash flow was -50.61B and capital expenditures 0, giving a free cash flow of -50.61B.
Operating Cash Flow | -50.61B |
Capital Expenditures | 0 |
Free Cash Flow | -50.61B |
FCF Per Share | -859.75 |
Margins
Gross margin is 92.66%, with operating and profit margins of -51.43% and -41.24%.
Gross Margin | 92.66% |
Operating Margin | -51.43% |
Pretax Margin | -44.45K% |
Profit Margin | -41.24% |
EBITDA Margin | -51.43K% |
EBIT Margin | -51.43% |
FCF Margin | -116.43K% |
Dividends & Yields
CRMD does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -4518.69% |
FCF Yield | -11529.55% |
Analyst Forecast
The average price target for CRMD is $15, which is 122.6% higher than the current price. The consensus rating is "Buy".
Price Target | $15 |
Price Target Difference | 122.6% |
Analyst Consensus | Buy |
Analyst Count | 7 |
Stock Splits
The last stock split was on Mar 26, 2019. It was a backward split with a ratio of 1:5.
Last Split Date | Mar 26, 2019 |
Split Type | backward |
Split Ratio | 1:5 |
Scores
Altman Z-Score | 3.16 |
Piotroski F-Score | 2 |